Aurora Cannabis held its 2026 Annual General Meeting virtually, with 26.86% of shares represented. Shareholders re-elected all nominated directors with over 85% approval and approved Ernst & Young LLP as auditors for the coming year. The advisory vote on executive compensation passed with nearly 83% support, signaling strong shareholder confidence. The company aims to continue focusing on its medical cannabis strategy and global growth to deliver long-term value to investors.
Aurora Cannabis has received an unsolicited takeover proposal from Curaleaf offering $4 per share, combining cash and Curaleaf shares. Aurora's board is reviewing the offer carefully, noting the price is lower than past trading values and emphasizing...
Curaleaf Holdings has made a hostile bid to acquire Aurora Cannabis, proposing $4 per share through a combination of Curaleaf shares and $0.75 cash per Aurora share. This offer represents a 45% premium over Aurora's recent average price and aims to m...
Curaleaf Holdings has proposed to acquire Aurora Cannabis by offering US$4.00 per share, including cash and Curaleaf shares, representing a 45% premium over Aurora's recent trading price. The deal aims to combine Aurora's EU-GMP cultivation and manuf...
